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Abstract 
Background: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma 
(HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins.
Methods: Surgically resected tumor tissues were obtained from 80 patients, including HCC tumor tissues, non-tumor 
tissues, and normal liver tissues. These samples were grouped in the discovery and validation sample sets. The expres-
sion level of 192 apoptosis-related proteins was monitored using 247 commercially available antibodies and western 
blotting. The intensity of protein bands was compared between the tumor and non-tumor tissues as well as between 
the patients who had recurrence within 2 years after surgery and those who did not.
Results: In the first screening, we used pooled samples. The intensity of 53 protein bands detected by 37 unique 
antibodies was higher in tumor tissues compared with normal liver tissues, especially tumor tissues from patients who 
had recurrence within 2 years after surgery. In the second screening, we examined individual samples used to make 
the pooled samples. Among the selected bands and antibodies, the intensity of 18 protein bands detected by 11 anti-
bodies was higher in tumor tissues compared with that in normal tissues, especially tumor tissues from the patients 
with early recurrence after surgery. For the third screening, we examined the samples from newly enrolled patients 
using these 11 antibodies. Eighteen protein bands detected by six antibodies were selected by using the same crite-
ria. The corresponding antigens included ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and PIASx1/2.
Conclusions: We screened 192 apoptosis-related proteins using specific antibodies and western blotting. We identi-
fied 6 apoptosis-related proteins associated with carcinogenesis and early recurrence in HCC. The biological and clini-
cal significance of the identified proteins are worth further investigation.
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Background
Hepatocellular carcinoma (HCC) is a major public health 
problem with especially high prevalence in Asia and 
Africa [1]. Recent studies indicate that HCC incidence 
has increased substantially in the US and UK over the 
last decades [2–4]. Surgery is the only curative treatment, 
and fewer than 15% of patients undergo surgery because 
of late clinical presentation and diagnosis. Survival for 
surgically incurable patients with HCC has not increased 
significantly over the past 30  years and, even after sur-
gical resection, the early recurrence prevents favorable 
clinical outcome after curative resection. As a conse-
quence, the overall 5-year survival rate remains at <5% in 
HCC [5]. Other treatment options such as molecular-tar-
geted therapies for patients with advanced or metastatic 
HCC are limited [6]. Therefore, novel diagnostic and 
therapeutic approaches or improvement of the existing 
ones have long been desired to improve the clinical out-
come of patients with HCC.
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Apoptosis is the major regulatory mechanism disturbed 
during carcinogenesis and cancer progression in HCC. 
Tumor cells are exposed to various apoptotic stimuli dur-
ing the carcinogenesis and metastasis steps, and fully 
transformed metastatic tumor cells acquire resistance 
against apoptotic stress [7]. Aberrant regulation of apopto-
sis-related proteins has been observed in more aggressive 
HCC cells. For example, anti-apoptotic regulators such as 
B cell lymphoma (Bcl)-2 family proteins have been identi-
fied as therapeutic targets in HCC [8, 9]. The expression of 
X-linked inhibitor-of-apoptosis protein promoted resist-
ance to apoptosis, enhanced the invasiveness of HCC cells, 
and was a biomarker for relapse in patients with HCC [10]. 
Apoptosis-associated receptors and ligands also play key 
roles in HCC progression and are considered as therapeu-
tic targets [11]. These observations strongly suggest that 
further investigation of the apoptosis pathway may reveal 
novel candidate biomarkers and therapeutic targets. How-
ever, although the apoptosis pathway includes hundreds 
of proteins, only a limited number of proteins have been 
investigated in the context of HCC, and the clinical appli-
cability of these proteins remained to be challenged.
Proteomic studies identified specific proteins with 
expression levels that are correlated with malignant fea-
tures of HCC [12–18]. Those that are implicated in early 
recurrence may be useful in the clinic as prognostic bio-
markers and drug targets. Separation-based proteomics 
technologies such as mass spectrometry and two-dimen-
sional differential gel electrophoresis (2D-DIGE) gener-
ate protein expression profiles based on the nature of the 
proteins. These methods provide opportunities for identi-
fying unexpected proteins as biomarkers and therapeutic 
targets. However, they do not fully cover certain molecular 
pathways. For example, we extensively examined protein 
expression in the surgically resected tissues from patients 
with HCC using mass spectrometry [18] and 2D-DIGE 
[15]. However, we found that the proteome data obtained in 
our previous studies did not cover most apoptosis-related 
proteins. The antibody-based proteomics is a powerful 
knowledge-based tool that allows investigators to examine 
the expression profiles of particular proteins and pathways.
In this study, we investigated the status of the apoptosis 
pathway in HCC using a panel of 247 commercial anti-
bodies against 192 proteins in surgically resected liver 
tissues. The expression of 192 apoptosis-associated pro-
teins was compared between non-tumor and tumor tis-
sues as well as between tumor tissues from patients with 
or without early recurrence after surgery.
Methods
Clinical samples
Surgically resected HCC tissues and adjacent non-tumor 
tissues were obtained from patients at the National 
Cancer Center Hospital who underwent initial hepatic 
resection between December 1999 and May 2005. The 
study was reviewed and approved by the Institutional 
Review Board of the National Cancer Center. Written 
informed consent was obtained from all participants 
in this study. Normal liver tissues were obtained from 
patients with colorectal cancer who underwent hepatic 
resection for metastatic liver tumors during the same 
period. Patients with HCC received curative surgery, but 
did not receive preoperative therapy. Tumors were clas-
sified according to the International Union against Can-
cer Tumor-node-metastasis Criteria. For the expression 
study, samples were divided into four groups: primary 
tumor tissue from patients with HCC who showed recur-
rence within 2 years after surgery (Group S), tumor tis-
sue from patients with HCC who did not show a relapse 
within 2  years after surgery (Group L), adjacent liver 
tissue from patients with HCC (Group A), and normal 
liver tissue from patients with colorectal cancer and liver 
metastasis (Group N). Samples were randomly divided 
into two groups for discovery and validation purposes. 
Detailed clinical and pathological data are summarized in 
Tables 1 and 2.
Protein extraction
Proteins were extracted from surgically resected tis-
sues as previously reported [19]. In brief, the frozen tis-
sues were powdered in liquid nitrogen using metal beads 
(Multi-beads shocker; Yasui-kikai, Osaka, Japan). The tis-
sues were then treated with urea lysis buffer (2 M thio-
urea, 6 M urea, 3% CHAPS, and 1% Triton X-100). After 
centrifugation, the supernatant was recovered as a solu-
ble protein fraction and stored at −80 °C until use.
Western blotting and image analysis
Protein expression levels were examined by western 
blotting. Five micrograms of protein were separated by 
sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) with various acrylamide concentra-
tions according to the expected molecular mass of target 
proteins (ATTO, Tokyo, Japan). The separated proteins 
were transferred to a nitrocellulose membrane, which 
was reacted with primary antibodies. We selected 192 
proteins as those associated with apoptosis, according to 
the pathway maps in MetaCore (GeneGo, St. Joseph, MI, 
USA) and Kyoto Encyclopedia of Genes and Genomes 
(KEGG; http://www.genome.jp/kegg). A list of 247 anti-
bodies against the 192 proteins along with the providers’ 
codes and their dilutions is provided in Additional file 1: 
Table S1. The dilutions of antibodies were determined 
according to the manufacturer’s instructions. An anti-
body for actin (A5060; Sigma-Aldrich, St. Louis, MO, 
USA) was used at 1:250 dilution as a loading control. A 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 7 of 12Morofuji et al. Clin Proteom  (2016) 13:28 
horseradish peroxidase-conjugated antibody (GE Bio-
sciences, Uppsala, Sweden) was used at 1:1000 dilution 
to detect the immuno-complex. The signal was visual-
ized by enhanced chemiluminescence (ECL Plus; GE Bio-
sciences) and an LAS-3000 system (GE Biosciences). The 
intensity of protein bands was measured using Image-
Quant image analysis software (GE Biosciences). Mem-
brane-to-membrane variations were normalized to the 
intensity of the actin band.
Statistical analysis
Overall survival and disease-free survival curves were 
generated using the Kaplan–Meier method [20]. Statisti-
cal analyses were performed using SPSS software (SPSS 
Inc., IBM, Chicago, IL, USA).
Results
To obtain the global expression profiles of apoptosis-
associated proteins, we examined the surgically resected 
tissues by western blotting. We selected 192 proteins 
based on the contents of MetaCore and KEGG pathway 
maps, for which 247 antibodies were used. Fifty-one of 
these antibodies recognized different epitopes of the 
same protein (Additional file 1: Table S1).
We examined the survival of patients with HCC and 
confirmed that patients with early recurrence presented 
shorter survival than those without recurrence (Fig.  1). 
These observations were in agreement with previous 
reports that the recurrence-free period is a critical prog-
nostic factor for HCC [21].
 The screening process to identify apoptosis-related 
proteins is illustrated in Fig.  2. In the first screening 
(Fig. 2a), we generated four sample pools consisting of 10 
samples from each groups, group N (normal liver tissue), 
A (adjacent liver tissue), L (tumor tissue without recur-
rence), and S (tumor tissue with recurrence within 2 years 
of surgery). The four group samples were subjected to 
western blotting (Table 1). The 247 antibodies generated 
629 protein bands in the pooled samples. For a compara-
tive analysis, we merged groups N and A as the non-
tumor group and Groups L and S as the tumor group. We 
selected protein bands that had >twofold intensity differ-
ences between these two groups. Examples of western 
blotting data are presented in Additional file 2: Figure S1. 
Fifty-five protein bands corresponding to 36 antibodies 
showed >twofold increased intensity and 55 bands cor-
responding to 33 antibodies showed >twofold decreased 
intensity in the tumor group. We compared groups L and 
S with respect to these 69 antibodies in order to identify 
proteins with concordant alterations during HCC car-
cinogenesis and progression. Twenty-six bands (19 anti-
bodies) and 27 bands (21 antibodies) showed a >twofold 
increase and decrease in intensity, respectively, in group 
S as compared to group L. Antibodies generated multiple 
protein bands. The protein bands generated by the same 
antibodies appeared to increase or decrease in intensity 
in group S. After accounting for the overlap between 
these two sets of protein bands and antibodies, 53 pro-
tein bands and 37 unique antibodies were selected.
For the second screening, we examined the individual 
samples used to generate the pooled samples and the 
selected 37 antibodies (Fig. 2b). The average intensity of 
nine protein bands (six antibodies) was increased, while 
that of 17 protein bands (11 antibodies) was decreased by 
>twofold in tumor tissues compared with non-tumor tis-
sues (Table 3). In addition, the average intensity of pro-
tein bands by four antibodies was increased, while that 
by eight antibodies was decreased by >twofold in group S 
samples. After accounting for the overlap between these 
two sets of protein bands and antibodies, 18 protein 
bands and 11 unique antibodies were selected. The inten-
sity levels of 18 protein bands detected by the 11 antibod-
ies are illustrated in the heat maps (Fig. 3a). 
In the third screening, we examined the selected 11 
antibodies using the 40 samples from the newly enrolled 
patients (Fig.  3b). The clinical and pathological data for 
the 40 patients are shown in Table 2. The average inten-
sity of 4 protein bands (4 antibodies) was increased, while 
that of nine protein bands (six antibodies) was decreased 
by >twofold in tumor tissues compared with that in non-
tumor tissues. In addition, the average intensity of two 
bands (two antibodies) was increased, while that of four 
bands (four antibodies) was decreased by >twofold in 
group S samples compared with those in group L. We 
demonstrated the intensity levels of six protein bands 
detected by the six antibodies are illustrated in the heat 
maps (Fig.  3c). The isoforms of six proteins included 
Fig. 1 Survival curves of the 40 patients with HCC included in this 
study. Overall survival is shown for the two groups of patients: group 
S did and group L did not have recurrence within 2 years of surgery 
(n = 20 each). The two groups presented distinct prognoses
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ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and 
PIASx1/2. The quantification of image intensity in Fig. 3 
is summarized in Additional file 3: Table S2, Additional 
file 4: Table S3, Additional file 5: Table S4.
We observed protein bands at unexpected locations 
on the gel, possibly resulting from posttranslational 
modifications such as phosphorylation and protein deg-
radation. For example, apaf-1 showed an unexpected 
molecular mass of 40 kDa (Fig. 4). A 30-kDa isoform was 
previously reported in the biologically inactive apopto-
some complex [22], indicating that the 40-kDa-apaf-1 pro-
tein band should be investigated in the context of HCC.
Fig. 2 Flow chart of the experimental procedure and results of first and second screenings. A panel of 247 antibodies for 192 apoptosis-associated 
proteins was screened in surgically resected HCC and adjacent normal tissue samples. Single antibodies generated multiple protein bands by 
western blotting. Band intensity was compared between samples. a First screening using four sample pools such as group N (normal liver tissue), A 
(adjacent liver tissue), L (tumor tissue without recurrence), and S (tumor tissue with recurrence within 2 years of surgery). b Second screening for the 
selected 37 antibodies
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Discussion
Early recurrence after surgical resection is a hallmark of 
poor prognosis in HCC and identifying the molecular 
components is critical for developing novel therapies. 
The association between apoptosis and HCC carcino-
genesis and progression has previously been suggested, 
and proteins in the apoptosis pathway are considered as 
biomarkers as well as therapeutic targets [8–11]. In con-
trast to previous studies that examined these proteins 
individually, we adopted a comprehensive approach and 
examined a panel of 247 antibodies in order to clarify the 
molecular events underlying early recurrence.
In this study, we used samples stratified according to 
the different status of recurrence after curative surgery 
(Tables  1, 2). As the early recurrence is associated with 
malignant features of tumor tissues, the patients with 
early recurrence were at a more advanced stage (Tables 1, 
2). Thus, the early recurrence biomarkers generated 
from this study are also those used for staging. Indeed, 
we detected significant correlations between early recur-
rence and poor prognosis (Fig. 1), and the proteins identi-
fied in this study may be associated with poor prognosis.
We used western blotting as a tool for examining pro-
tein expression. Western blotting allows the visualization 
of intact proteins using specific antibodies along with 
their isoforms with distinct molecular mass. Previous 
studies indicated that alternatively spliced isoforms of 
various proteins are associated with cancer phenotypes 
[23–27]. Western blotting has long been used in can-
cer research and may be particularly useful for studying 
aberrant protein isoforms, especially when used in com-
bination with an antibody library.
Western blotting has drawbacks. Paramount among 
these is that the results may be affected by non-specific 
antibody reactions. In the present study, multiple bands 
corresponding to target proteins appeared at differ-
ent locations than those predicted by their amino acid 
sequence. These were nonetheless included in the analy-
sis since they do not necessarily reflect non-specific reac-
tions; they may be novel cleavage fragments that have 
diagnostic utility. In a previous study, we reported an 
association between a novel variant of STAT3 and vas-
cular invasion in HCC that was identified by SDS-PAGE 
combined with mass spectrometry [18], which can help 
validating western blotting data. The use of mass spec-
trometry and the different antibodies against the same 
proteins, but different epitopes, may be helpful to con-
firm the protein identity. The linear dynamic range of 
western blotting signal is also a subject of discussion. 
For wider dynamic range, the use of fluorescence-based 
detection may be worth considering.
We identify six proteins whose band intensities were 
associated with early recurrence in HCC (Fig. 3c). Those 
included ERK1 and Bclx, the aberrant regulations of 
Table 3 The 11 antibodies in western blotting screening
Protein name Fold difference (Ratio of median) Pathway
Test set Validation set
NA versus LS L versus S NA versus LS L versus S
Apaf-1 band 4 0.160 0.106 0.177 0.343 Caspase cascade
Bclx band 1 0.150 0.104 0.777 0.771 Mitochondrial pathway
Bclx band 2 0.283 0.050 0.622 0.377 Mitochondrial pathway
Bclx band 3 0.104 0.155 0.244 0.268 Mitochondrial pathway
Bclx band 4 0.220 0.214 0.746 0.913 Mitochondrial pathway
CD120a/TNF-R1 band 2 0.324 0.376 0.519 0.836 Extrinsic pathway
CD120a/TNF-R1 band 3 0.196 0.368 0.339 0.806 Extrinsic pathway
FADD band 2 0.176 0.395 0.408 0.721 Extrinsic pathway
p38MAPK band 2 0.402 0.404 0.576 0.722 Extrinsic pathway
phospho-c-Abl(pTyr412) band 1 0.362 0.413 0.295 0.475 Extrinsic pathway
PIASx1/2 (C-term) band 2 0.201 0.270 0.216 0.304 p53 banding pathway
14-3-3zeta band 2 0.499 0.328 0.774 0.453 p53 banding pathway
14-3-3zeta band 5 2.220 3.780 1.099 1.105 p53 banding pathway
ERK1 band 1 2.715 2.017 5.996 2.040 Extrinsic pathway
PKG band 1 3.874 2.548 2.635 2.027 Extrinsic pathway
Stat1(C-terminus) band 2 8.270 2.801 1.748 1.225 Caspase cascade
Stat1(C-terminus) band 4 2.058 6.237 2.119 1.696 Caspase cascade
Stat1(C-terminus) band 5 2.221 4.080 1.518 1.399 Caspase cascade
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Fig. 3 Heat map of antigens recognized by 11 selected antibodies. Band intensities were normalized among samples and blots. Measured intensi-
ties are displayed as a heat map. a In the first screening, the intensity of 18 protein bands for 11 antibodies was up- or downregulated in HCC 
carcinogenesis and progression. b In the next screening, we examined the selected 11 antibodies using the 40 samples from the newly enrolled 
patients. c In the independent validation study, the intensity of six bands for six antibodies differed among sample groups. The quantitative data for 
western blotting images are presented in Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4
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which were associated with poor prognosis in HCC in 
previous studies [28–33]. Several ERK inhibitors are 
currently in clinical trials and the functional contribu-
tions of ERK families are worth investigating in HCC [34, 
35]. Further validation studies of identified proteins are 
required for clinical applications.
In conclusion, we used a panel of antibodies against 
proteins in the apoptosis pathway to identify those asso-
ciated with early HCC recurrence. Our results indicated 
that western blotting using specific antibodies can be 
a powerful tool to investigate the expression of selected 
protein groups and to capture the overall views of given 
molecular events in cancer. This approach can be applied 
to other protein groups in cancer proteomics. West-
ern blot is the only method that separates the proteins 
according to their molecular mass and measures them 
individually with high sensitivity. Thus, the conventional 
clinical examination modalities such as IHC and ELISA 
may not be adequate as the modalities to apply the west-
ern blotting results to clinical applications. We may need 
to develop novel innovative clinical examination modali-
ties, including a fully automated western blotting system.
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Additional file 1: Table S1. List of antibodies examined in this study.
Additional file 2: Figure S1. Western blotting data of six proteins, which 
were associated with early recurrence in HCC.
Additional file 3: Table S2. Normalized intensity of protein bands in 
Individual 40 samples in Group N, A, L, and S.
Additional file 4: Table S3. Normalized intensity of protein bands in 
newly enrolled 40 samples in Group N, A, L, and S.
Additional file 5: Table S4. Normalized intensity of protein bands in 
newly enrolled 40 samples in Group N, A, L, and S.
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